Spots Global Cancer Trial Database for Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Study Description

Brief Summary: RATIONALE: Monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8 and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroblastoma by blocking blood flow to the tumor. Giving iodine I 131 monoclonal antibody 3F8 together with bevacizumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 monoclonal antibody 3F8 when given together with bevacizumab in treating patients with relapsed or refractory neuroblastoma.

Detailed Description: OBJECTIVES: Primary * Determine the toxicity of iodine I 131 monoclonal antibody 3F8 (\^131I-3F8) and bevacizumab in patients with relapsed or refractory neuroblastoma. * Determine the hematopoietic recovery after autologous stem cell rescue in patients treated with this regimen. Secondary * Determine the clinical response rates in patients treated with this regimen. * Assess whole body dosimetry for \^131I-3F8. * Assess tumor targeting of \^131I-3F8 before and after bevacizumab. OUTLINE: This is a dose-escalation study of iodine I 131 monoclonal antibody 3F8 (\^131I-3F8). Patients receive \^131I-3F8 IV over 20-30 minutes on day 0 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 courses. Patients whose blood counts do not recover and whose human antimouse antibody (HAMA) titer \< 1,000 U/mL after course 1 receive one dose of \^131I-3F8 alone followed by autologous stem cell rescue (ASCR) and filgrastim (G-CSF). Patients whose blood counts do not recover and whose HAMA titer ≥ 1,000 U/mL after course 1 undergo ASCR followed by G-CSF. Patients whose blood counts recover and whose HAMA titer \< 1,000 U/mL after course 1 receive 3 more courses of \^131I-3F8 and bevacizumab in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of \^131I-3F8 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. After completion of study treatment, patients are followed at 3-4 weeks and then every 3-6 months thereafter.

Keywords

Eligibility

Minimum Age: 1 Year

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial